157 related articles for article (PubMed ID: 15232997)
1. Drugs take the spotlight in steering clinical, economic direction for ESRD.
Neumann ME
Nephrol News Issues; 2004 Jun; 18(7):50-1. PubMed ID: 15232997
[No Abstract] [Full Text] [Related]
2. Managed care is not the "cure-all" for improving quality and controlling costs in ESRD.
Amerling R
Nephrol News Issues; 1999 Apr; 13(4):46-7. PubMed ID: 10418448
[No Abstract] [Full Text] [Related]
3. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
4. Can a global payment system work for the ESRD program?
Burton B; Day LM; Pierpoint KL; Vlchek DL
Nephrol News Issues; 1993 Oct; 7(10):18, 20, 22-3. PubMed ID: 8232628
[No Abstract] [Full Text] [Related]
5. Caring for ESRD patients.
Andriote JM
Healthplan; 1998; 39(4):33-5. PubMed ID: 10351321
[No Abstract] [Full Text] [Related]
6. Adapting to changes in Medicare cost report requirements.
Rossi T
Nephrol News Issues; 2005 Sep; 19(10):36-9. PubMed ID: 16187645
[No Abstract] [Full Text] [Related]
7. ESRD data system needs a fix. Lack of updates impacts beneficiaries, costs Medicare; USRDS looks elsewhere for accurate data.
Nephrol News Issues; 2002 Apr; 16(5):8, 10. PubMed ID: 11962159
[No Abstract] [Full Text] [Related]
8. In a bundling era, finding a fair price for ESRD services.
Sullivan JD
Nephrol News Issues; 2007 Mar; 21(4):37, 39-40. PubMed ID: 17393926
[No Abstract] [Full Text] [Related]
9. Medicare prescription plan, threat to AWP could impact the ESRD drug market.
Neumann ME
Nephrol News Issues; 2003 Jan; 17(2):16-7, 21. PubMed ID: 12629823
[No Abstract] [Full Text] [Related]
10. ESRD as a window into America's cost crisis in health care.
Knauf F; Aronson PS
J Am Soc Nephrol; 2009 Oct; 20(10):2093-7. PubMed ID: 19729435
[No Abstract] [Full Text] [Related]
11. Lessons for Medicare Part D in the hemodialysis community.
Nayeem AI; Chertow GM
BMC Nephrol; 2006 Jul; 7():11. PubMed ID: 16824211
[TBL] [Abstract][Full Text] [Related]
12. Medicare prescription drug coverage (part D): challenges and opportunities.
Witten B
Nephrol News Issues; 2006 Aug; 20(9):14-6, 18. PubMed ID: 16916055
[No Abstract] [Full Text] [Related]
13. Re-engineering the ESRD Program amid Medicare reform.
Neumann ME
Nephrol News Issues; 2005 Jan; 19(2):40-1. PubMed ID: 15717573
[No Abstract] [Full Text] [Related]
14. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis.
Nissenson AR; Dylan ML; Griffiths RI; Yu HT; Dean BB; Danese MD; Dubois RW
Am J Kidney Dis; 2005 Aug; 46(2):301-8. PubMed ID: 16112049
[TBL] [Abstract][Full Text] [Related]
15. Evidence missing to support moving ESRD patients into HMOs.
Charytan C
Nephrol News Issues; 2000 Jul; 14(8):13-4. PubMed ID: 12101515
[No Abstract] [Full Text] [Related]
16. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
Deverka PA; McLeod HL
Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
[TBL] [Abstract][Full Text] [Related]
17. The drug add-on component--have all provider types seen budget neutrality?
Mentz K
Nephrol News Issues; 2005 Sep; 19(10):42-4. PubMed ID: 16187646
[No Abstract] [Full Text] [Related]
18. End-stage renal disease: managing quality and cost.
Li C
Health Care Innov; 1998; 8(6):32-3. PubMed ID: 10339327
[No Abstract] [Full Text] [Related]
19. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of Medicare Part D in the end-stage renal disease population.
St Peter WL
Adv Chronic Kidney Dis; 2008 Apr; 15(2):140-6. PubMed ID: 18334238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
